EUCTR2006-003431-78-NL进行中（未招募）1 期
A Multicenter, Observational Study of the Long-term Safety of Infliximab (REMICADE®) in Subjects with Moderate to Severe Chronic Obstructive Pulmonary disease (COPD) - RESULTS COPD
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Centocor BV
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All consenting subjects who received at least 1 dose of study agent in either the Centocor sponsored Phase 2 clinical study (C0168T54) or in the 2 Centocor-sponsored IIS studies (EU0016 C0168X09 and EU0073 C0168X57) of infliximab in subjects with COPD.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who are unwilling to respond to requests for long-term safety information will be excluded.
研究者
相似试验
进行中（未招募）
1 期
ong-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus ErythematosusSystemic Lupus ErythematosusEUCTR2018-003471-35-PLBristol-Myers Squibb International Corporation360
进行中（未招募）
1 期
ong-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus ErythematosusMedDRA version: 21.1Level: LLTClassification code 10042947Term: Systemic lupus erythematosus syndSystem Organ Class: 100000004859Systemic Lupus ErythematosusEUCTR2018-003471-35-ROBristol-Myers Squibb International Corporation360
进行中（未招募）
1 期
ong-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus ErythematosusMedDRA version: 21.1Level: LLTClassification code 10042947Term: Systemic lupus erythematosus syndSystem Organ Class: 100000004859Systemic Lupus ErythematosusEUCTR2018-003471-35-HUBristol-Myers Squibb International Corporation360
进行中（未招募）
1 期
ong-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus ErythematosusSystemic Lupus ErythematosusCTIS2022-502444-13-00Bristol Myers Squibb International Corporation261
进行中（未招募）
1 期
ong-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus ErythematosusSystemic Lupus ErythematosusEUCTR2018-003471-35-ESBristol-Myers Squibb International Corporation360